Moxonidine in Patients Undergoing Vascular Surgery

The Effects of Small Doses of Moxonidine in Patients Undergoing Vascular Surgery

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00244504

Enrollment

141

Registered

2005-10-26

Start date

2002-11-30

Completion date

2006-03-31

Last updated

2009-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease, Vascular Surgery

Brief summary

Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months

Interventions

DRUGmoxonidine

moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* abdominal aortic or peripheral vascular surgery

Exclusion criteria

* unstable angina, * severe symptomatic heart failure (NYHA IV) * systolic blood pressure at rest \< 100 mmHg * bradycardia (\<50/min) * higher grade AV heart block * creatinine clearance \< 30 ml/min * pregnancy * no consent

Design outcomes

Primary

Measure	Time frame
over-all mortality	30 days and 12 months

Secondary

Measure	Time frame
Ischemia detected by Holter-ECG ST alterations or troponin T elevation	7 days

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026